Cutler Group LP Next Cure, Inc. Transaction History

Cutler Group LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	SELL	$1.2 - $2.49 $120 - $249	-100 Reduced 12.5%	700 $0
Q1 2021 Apr 26, 2021	BUY	$9.81 - $13.88 $2,943 - $4,164	300 Added 60.0%	800 $8,000
Q3 2020 Oct 27, 2020	SELL	$8.15 - $21.17 $4,890 - $12,702	-600 Reduced 54.55%	500 $4,000
Q2 2020 Jul 22, 2020	BUY	$21.19 - $40.2 $21,190 - $40,200	1,000 Added 1000.0%	1,100 $23,000
Q1 2020 May 07, 2020	SELL	$32.32 - $58.37 $42,016 - $75,881	-1,300 Reduced 92.86%	100 $3,000

Q4 2019 Feb 06, 2020	BUY	$25.0 - $92.22 $35,000 - $129,108	1,400 New	1,400 $78,000

15.9M

10.5K

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $46.9M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.